文献速递消化、代谢与肾脏急症心脑血管急症

2型糖尿病强化血糖控制的15年随访

Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up.
PubMed 文献 · N Engl J Med · 2019-01-01
一句话结论强化血糖控制5.6年仅在糖化血红蛋白曲线分离期间降低心血管事件风险,无遗留效应或死亡率获益。

该研究对1791例2型糖尿病退伍军人进行观察性随访,比较强化与标准降糖治疗。在15年随访期间,强化治疗组主要心血管事件风险未显著低于标准治疗组(HR 0.91,95%CI 0.78-1.06,P=0.23),死亡风险也无差异(HR 1.02,95%CI 0.88-1.18)。仅在糖化血红蛋白曲线分离的延长期间,主要心血管事件风险降低(HR 0.83,95%CI 0.70-0.99),但曲线重合后此获益未持续(HR 1.26,95%CI 0.90-1.75)。结论提示强化血糖控制无遗留效应或死亡率获益。

要点

  • 15年随访中,强化治疗组主要心血管事件风险未显著低于标准治疗组(HR 0.91,95%CI 0.78-1.06,P=0.23)。
  • 强化治疗组全因死亡风险与标准治疗组无显著差异(HR 1.02,95%CI 0.88-1.18)。
  • 仅在糖化血红蛋白曲线分离期间,强化治疗组主要心血管事件风险降低(HR 0.83,95%CI 0.70-0.99)。
  • 曲线重合后,强化治疗组主要心血管事件风险未持续降低(HR 1.26,95%CI 0.90-1.75)。
  • 强化血糖控制无遗留效应或死亡率获益。

适用人群与场景

  • 1791例2型糖尿病退伍军人,随机分配至强化或标准降糖治疗。

研究设计与关键结果

  • 研究类型为随机对照试验的观察性随访,纳入1791例2型糖尿病退伍军人,强化治疗组892例,标准治疗组899例。
  • 试验期间强化治疗组与标准治疗组糖化血红蛋白曲线平均分离1.5个百分点,试验结束后3年差异降至0.2-0.3个百分点。
  • 15年随访期间,强化治疗组主要心血管事件风险未显著低于标准治疗组(HR 0.91,95%CI 0.78-1.06,P=0.23)。
  • 15年随访期间,强化治疗组死亡风险与标准治疗组无显著差异(HR 1.02,95%CI 0.88-1.18)。
  • 在糖化血红蛋白曲线分离的延长期间,强化治疗组主要心血管事件风险降低(HR 0.83,95%CI 0.70-0.99)。
  • 糖化血红蛋白水平重合后,强化治疗组主要心血管事件风险未显著降低(HR 1.26,95%CI 0.90-1.75)。

证据类型、等级与局限

  • 证据类型:随机对照试验的观察性随访。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,强化血糖控制仅在糖化血红蛋白曲线分离期间降低心血管事件风险,无遗留效应或死亡率获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: We previously reported that a median of 5.6 years of intensive as compared with standard glucose lowering in 1791 military veterans with type 2 diabetes resulted in a risk of major cardiovascular events that was significantly lower (by 17%) after a total of 10 years of combined intervention and observational follow-up. We now report the full 15-year follow-up.

METHODS: We observationally followed enrolled participants (complete cohort) after the conclusion of the original clinical trial by using central databases to identify cardiovascular events, hospitalizations, and deaths. Participants were asked whether they would be willing to provide additional data by means of surveys and chart reviews (survey cohort). The prespecified primary outcome was a composite of major cardiovascular events, including nonfatal myocardial infarction, nonfatal stroke, new or worsening congestive heart failure, amputation for ischemic gangrene, and death from cardiovascular causes. Death from any cause was a prespecified secondary outcome.

RESULTS: There were 1655 participants in the complete cohort and 1391 in the survey cohort. During the trial (which originally enrolled 1791 participants), the separation of the glycated hemoglobin curves between the intensive-therapy group (892 participants) and the standard-therapy group (899 participants) averaged 1.5 percentage points, and this difference declined to 0.2 to 0.3 percentage points by 3 years after the trial ended. Over a period of 15 years of follow-up (active treatment plus post-trial observation), the risks of major cardiovascular events or death were not lower in the intensive-therapy group than in the standard-therapy group (hazard ratio for primary outcome, 0.91; 95% confidence interval [CI], 0.78 to 1.06; P = 0.23; hazard ratio for death, 1.02; 95% CI, 0.88 to 1.18). The risk of major cardiovascular disease outcomes was reduced, however, during an extended interval of separation of the glycated hemoglobin curves (hazard ratio, 0.83; 95% CI, 0.70 to 0.99), but this benefit did not continue after equalization of the glycated hemoglobin levels (hazard ratio, 1.26; 95% CI, 0.90 to 1.75).

CONCLUSIONS: Participants with type 2 diabetes who had been randomly assigned to intensive glucose control for 5.6 years had a lower risk of cardiovascular events than those who received standard therapy only during the prolonged period in which the glycated hemoglobin curves were separated. There was no evidence of a legacy effect or a mortality benefit with intensive glucose control. (Funded by the VA Cooperative Studies Program; VADT ClinicalTrials.gov number, NCT00032487.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Reaven PD, Emanuele NV, Wiitala WL, et al. Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up. N Engl J Med. 2019. PMID: 31167051. doi:10.1056/NEJMoa1806802

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。